Incyte’s povorcitinib shows strong results in hidradenitis suppurativa trial
PositiveFinancial Markets

Incyte's recent trial of povorcitinib for treating hidradenitis suppurativa has shown promising results, indicating a potential breakthrough for patients suffering from this painful skin condition. The positive outcomes not only highlight the effectiveness of the drug but also bring hope to those who have struggled with limited treatment options. This development could significantly improve the quality of life for many individuals affected by this chronic disease.
— Curated by the World Pulse Now AI Editorial System